Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Anchiano Therapeutics stock
Own Anchiano Therapeutics stock in just a few minutes.
Anchiano Therapeutics Ltd is a biotechnology business based in the US. Anchiano Therapeutics shares (ANCN) are listed on the NASDAQ and all prices are listed in US Dollars. Anchiano Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of USD0.00.
How to buy shares in Anchiano Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Anchiano Therapeutics. Find the stock by name or ticker symbol: ANCN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Anchiano Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Anchiano Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Anchiano Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Anchiano Therapeutics share price
Use our graph to track the performance of ANCN stocks over time.Anchiano Therapeutics shares at a glance
Information last updated 2021-04-04.
| 52-week range | USD$11.20 - USD$94.40 |
|---|---|
| 50-day moving average | USD$61.36 |
| 200-day moving average | USD$34.74 |
| Wall St. target price | USD$1.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-5.21 |
Buy Anchiano Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Anchiano Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Anchiano Therapeutics financials
| Gross profit TTM | USD$0 |
|---|---|
| Return on assets TTM | -52.84% |
| Return on equity TTM | -125.6% |
| Profit margin | 0% |
| Book value | $7.71 |
| Market capitalisation | USD$34.9 million |
TTM: trailing 12 months
Shorting Anchiano Therapeutics shares
There are currently 65,165 Anchiano Therapeutics shares held short by investors – that's known as Anchiano Therapeutics's "short interest". This figure is 65.7% down from 190,175 last month.
There are a few different ways that this level of interest in shorting Anchiano Therapeutics shares can be evaluated.
Anchiano Therapeutics's "short interest ratio" (SIR)
Anchiano Therapeutics's "short interest ratio" (SIR) is the quantity of Anchiano Therapeutics shares currently shorted divided by the average quantity of Anchiano Therapeutics shares traded daily (recently around 3.3 million). Anchiano Therapeutics's SIR currently stands at 0.02. In other words for every 100,000 Anchiano Therapeutics shares traded daily on the market, roughly 20 shares are currently held short.
However Anchiano Therapeutics's short interest can also be evaluated against the total number of Anchiano Therapeutics shares, or, against the total number of tradable Anchiano Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anchiano Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Anchiano Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Anchiano Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anchiano Therapeutics.
Find out more about how you can short Anchiano Therapeutics stock.
Anchiano Therapeutics share dividends
We're not expecting Anchiano Therapeutics to pay a dividend over the next 12 months.
Anchiano Therapeutics share price volatility
Over the last 12 months, Anchiano Therapeutics's shares have ranged in value from as little as $11.2002 up to $94.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anchiano Therapeutics's is 0.9598. This would suggest that Anchiano Therapeutics's shares are less volatile than average (for this exchange).
Anchiano Therapeutics overview
Anchiano Therapeutics Ltd. , a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapeutics. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd.
Frequently asked questions
More guides on Finder
-
How to buy TREB-U stock
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
-
How to buy Trean Insurance Group stock
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
-
How to buy Trident Acquisitions stock
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
-
How to buy Trebia Acquisition stock
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
-
How to buy TREB-WS stock
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
-
How to buy TransDigm Group Incorporated stock
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
-
How to buy TransAct Technologies Incorporated stock
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
-
How to buy Trane Technologies stock
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
-
How to buy Tronox stock
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
-
How to buy trivago N-V stock
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.
Ask an Expert